Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02353728 · ClinicalTrials.gov registry record · Phase 2
Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT02353728 is a Phase 2 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 16 participants.
The verdict
NCT02353728, a Phase 2 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
The study is an open-label phase 2 clinical and translational trial designed to evaluate the effects of nilotinib on the leukemic stem cell population in subjects with newly diagnosed chronic phase chronic myeloid leukemia (Ph+ CML in CP). Nilotinib is FDA-approved to treat subjects with Ph+ CML in CP. Subjects on study will be monitored according to accepted National Cancer Comprehensive Network \[NCCN\] clinical guidelines for 24 months. After 24 months, if continued therapy is needed subjects will be transitioned to commercial supply of study drug.
Interventions
- DRUG Nilotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-01 |
| Est. Completion | 2021-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02353728
The ClinicalTrials.gov registry entry for NCT02353728 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nilotinib is the first listed.
NCT02353728 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02353728 about?
NCT02353728 is a clinical study titled "Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy". The study is an open-label phase 2 clinical and translational trial designed to evaluate the effects of nilotinib on the leukemic stem cell population in subjects with newly diagnosed chronic phase chronic myeloid leukemia (Ph+ CML in CP). Nilotinib is FDA-approved to treat subjects with Ph+ CML in ...
What is the current status of trial NCT02353728?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2015-01. Estimated completion is 2021-02.
What interventions are being tested in trial NCT02353728?
The interventions under investigation include: Nilotinib (DRUG).
Who is sponsoring clinical trial NCT02353728?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.